Pharma

CDMO player OneSource expands GLP-1 drug-device capacity as demand soars

OneSource Specialty Pharma recently raised Rs 801 crore through equity issuance

Six pharma companies sign MoUs with Telangana govt for Pharma City

Six prominent pharmaceutical companies, including Dr Reddy's Laboratories, Aurobindo Pharma, and Hetero Labs, have signed memorandums of understanding (MoUs) with the Telangana government to set up facilities in the Pharma City near here, the government announced on Friday. The companies have committed to invest over Rs 5,260 crore, which is expected to create 12,490 job opportunities in the pharma sector, according to an official release. Representatives from the companies met with Chief Minister A Revanth Reddy and Industries Minister D Sridhar Babu at the Secretariat to finalise the agreements. "The pharma company managements signed MoUs to establish the industries. The six companies expressed their interest to invest more than Rs 5260 crore. The investments will provide 12,490 job opportunities in the pharma sector. The government will allocate land for the establishment of the new pharma manufacturing units in the recognised pharma city, the release said. According to the MoUs

Indian pharma market registers over 5% growth in Sept 2024: Pharmarack

This comes even as the IPM registered a negative unit growth of -2.3 per cent, with only anti-diabetic and urology therapy segments recording significant unit growth of 3.1 per cent and 5.4 per cent

Pharmaceutical firms up their game to crackdown on spurious drugs

The concluding part of the series delves into strategies being applied by leading drug firms to battle counterfeits

Entod Pharma meets DCGI, issues clarification over eye drop 'claims'

Move comes after drug regulator had suspended nod granted to firm to manufacture, sell PresVu eye drops

PLI scheme: 50 units to be set up for pharma, medical device manufacturing

As many as 50 new greenfield plants are in the pipeline to come up in the next two years under the Production-linked Incentive (PLI) scheme for pharma and medical devices manufacturing, a senior government official said on Thursday. Speaking at the Annual Pharma Summit organised by industry body Assocham, Department of Pharmaceuticals Secretary Arunish Chawla said as the 'Make in India' initiative completes ten years, already 50 plants have been set up under the PLI schemes for the two sectors. "The PLI schemes in the pharma and meditech sectors have been a roaring success, 50 brand new greenfield pharma and medical device manufacturing plants have already become operational, and 50 more are in the pipeline," he said. When asked on the sidelines of the summit when the 50 new greenfield plants will come up, he said, "Everything will be completed in the next two years." Elaborating on the success of the PLI schemes, Chawla said, "In the last two years alone, the PLI plants have ...

Union health ministry approves new treatment for multi-drug resistant TB

The Union health ministry has approved the introduction of the BPaLM regimen, a novel treatment for multi-drug resistant tuberculosis (MDR-TB) under its National TB Elimination Program (NTEP) as a highly effective and shorter treatment option. This regimen includes a new anti-TB drug namely Pretomanid in combination with Bedaquiline and Linezolid (with or without Moxifloxacin), the ministry said in a statement.\ Pretomanid has earlier been approved and licensed for use in India by the Central Drugs Standard Control Organization (CDSCO). The BPaLM regimen, which consists four-drug combination -- Bedaquiline, Pretomanid, Linezolid and Moxifloxacin -- has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure, the ministry said. "While traditional MDR-TB treatments can last up to 20 months with severe side effects, BPaLM regimen can cure the drug-resistant TB in just six months with a high treatment success rate," the stateme

Indian pharma market registers over 6% growth in July '24: Pharmarack

"Seasonality-driven molecules and molecular combinations, especially anti-infectives, have shown a relatively stronger volume-driven growth," the firm stated in its report

USAID, Takeda Biopharma launch dengue prevention programme across India

The vaccine is already available for children and adults in the private market in Europe, Indonesia, and Thailand, and in some public programmes in Argentina and Brazil

Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook

Firm has a bunch of products lined up which will ensure limited earnings dip in FY27: Analysts

Pharma industry body mulling policy framework to guide cos on cybercrime

The Indian pharma companies are better off in terms of facing cyber-attacks now as compared to a few years ago

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Among individual players, Aurobindo Pharma, Dr Reddys Labs, and Zydus Lifesciences sourced 48 per cent, 47 per cent, and 46 per cent of their total revenues from the US generics segment, respectively

Gland Pharma surges 11% amidst stellar Q4 results; profits grow two fold

On Wednesday, Gland Pharma reported a two fold jump or 145 per cent increase in consolidated net profit, reaching Rs 192.4 crore for the January-March period of FY24

Promoter of Granules India sells 3.09% stake for Rs 304 cr via open market

Krishna Prasad Chigurupati, one of the promoters of Granules India, on Wednesday pared a 3.09 per cent stake in the company for Rs 304 crore through an open market transaction. According to the block deal data available on the NSE, Krishna Prasad Chigurupati offloaded 75 lakh shares, amounting to a 3.09 per cent stake in Granules India. The shares were disposed of at an average price of Rs 405.08 apiece, taking the deal size to Rs 303.81 crore, as per the data on the National Stock Exchange (NSE). According to a regulatory filing on Wednesday, Granules India said the primary objectives of the deal was to clear personal debt, to release the existing pledge on his holding in the company, and creating a small personal liquidity. "Chigurupati further notified the company that he has no plans to sell his shareholding in Granules India Ltd in the foreseeable future. "Post this transaction, the total promoter & promoter group shareholding in the company has changed from 41.96 per cent to

Sun Pharma Q4 Preview: Profits may grow up to 41% on higher specialty sales

Sun Pharma is set to see a strong financial earnings on a year-on-year (Y-o-Y) basis for Q4FY23, showing a 8-14 per cent Y-o-Y jump in its topline

Cipla Q4 Results Preview: Profits may jump up to 75% on higher volumes

Cipla may show a 3-10 per cent jump in its topline year-on-year (Y-o-Y), registering revenues in the range of Rs 5,939 crore and Rs 6,292 crore

Dr Reddy's Labs slumps 5% as brokerages give 'Reduce' call post Q4 earnings

The miss was driven by lower Revlimid sales, muted growth across markets and higher R&D spends. While the prevailing US tailwinds provide stability, absence of any meaningful approvals for Dr Reddy's

Q4 Results Preview: Lupin may see strong topline, bottomline growth

Indian pharmaceutical major Lupin is set to witness a strong financial earnings on a year-on-year (Y-o-Y) basis for the fourth quarter of the financial year 2023-24 (Q4FY23)

Morgan Stanley PE, India Life Sciences Fund inject Rs 1,000 cr into Maiva

Maiva Pharma on Thursday said it has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund. The transaction includes both primary and secondary funding, the Bengaluru-based pure play injectables contract development and manufacturing organisation said. The two investors have jointly acquired a controlling stake from existing investors and also infused primary capital into the company, an official statement said, without disclosing the stakes picked up. This is Maiva's first private equity fundraise and the proceeds will be used to set up a new manufacturing facility near Karnataka's Hosur with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables. It already has a facility in Hosur approved by the USFDA and other regulators that manufacture vials. "This fundraise will be used to add more vial, lyophilisation, and suspension capacity and introduce new manufacturing capabilities such as ...

Ayurveda products market in India to reach Rs 1.2 trillion by FY28: Report

India's Ayurveda product market is projected to reach USD 16.27 billion or Rs 1.2 lakh crore by FY28 from USD 7 billion or Rs 57,450 crore at present, according to a study. Ayurveda product market has experienced significant growth due to rising demand for natural and herbal remedies in local and international markets, increase in ayurvedic medical practitioners, government initiatives, and emergence of new entrepreneurs, Ayurveda tech startup NirogStreet said. Citing a survey, NirogStreet said the Ayurveda product market in India is expected to grow significantly, with projections indicating a substantial increase in market value to Rs 1,20,660 crore (USD 16.27 billion) by FY28. According to NirogStreet survey, the overall market for Ayurveda products and services is expected to grow at a CAGR of 15 per cent from FY23 to FY28, with the product and service sectors growing at a CAGR of 16 per cent and 12.4 per cent, respectively. The survey also estimated the value of the country's